By Kristy Dorsey

Omega Diagnostics has signed a supply agreement for one line of its Covid testing kits in a deal that will use some manufacturing capacity at its headquarters in Alva while it awaits a long-overdue decision on the UK Government’s testing requirements.

The agreement as exclusive supplier of its professional-use lateral flow test (LFT) to Liverpool-based DAM Health, a provider of “fit to fly” certification services, has led to an initial purchase order worth more than £750,000. DAM currently uses about 200,000 tests per month within its network of more than 100 clinics across the UK and Europe.

This could be expanded to include an at-home version of the antigen LFT, which determines whether someone is currently infected with the virus. An application to sell it as a self-testing kit was filed in August, with a decision expected by the end of this year.

READ MORE: Omega Diagnostics files for European approval of self-testing Covid-19 kits

The agreement might also be extended to include the sale by DAM of Omega’s Food Detective product, which detects a variety of food allergies. There is a further provision to expand geographically beyond Europe as DAM grows its international network.

In a statement, Omega said the agreement will allow it to honour its existing commitments to the Department of Health and Social Care (DHSC), which in February selected Omega as one of a handful of manufacturers to supply the Government with Covid test kits.

By the end of April, Omega was due to have capacity in place to produce up to two million tests per week on behalf of the Government. However, the DHSC has yet to decide on which test it favours, one of which was developed by Bedford-based Mologic, a partner of Omega’s in a separate Covid test manufacturing agreement.

READ MORE: Omega shares fall on Mologic test woes

Omega chief executive Colin King said the deal with DAM Health was the result of an active search for commercial partners in which it was supported by Lansdown Strategic Capital.

“Reaching a commercial agreement with a leading and fast-growing testing provider is a major milestone for the company in bringing our gold-standard test to market and we look forward to working collaboratively with DAM Health and are hopeful that this partnership can be broadened to cover more of Omega’s products, not just in the Covid space,” he added.

Share in Omega, which reached highs of more than 100p in October 2020, closed 2p higher yesterday at 51.5p.